Guru Sonpavde: Adjuvant pembrolizumab improved outcomes in MIBC

Guru Sonpavde, Genitourinary Oncology and Phase I Clinical Trials Director of Chair of Bladder Cancer Research at AdventHealth Central Florida, shared a post on LinkedIn, about recent paper published in The New England Journal of Medicine:

Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma.

Authors: Andrea B. Apolo, Karla V. Ballman, Guru Sonpavde, Stephanie Berg, William Y. Kim, Rahul Parikh, Min Yuen Teo, Randy F. Sweis, Daniel M. Geynisman, Petros Grivas, Gurkamal Chatta, Zachery Roger Reichert, Joseph W. Kim, Mehmet Asim Bilen, Bradley McGregor, Parminder Singh, Abhishek Tripathi, Suzanne Cole, Nicholas Simon, Scot Niglio, Lisa Ley, Lisa Cordes, Sandy Srinivas, Jiaoti Huang, Meagan Odegaard, Colleen Watt, Daniel Petrylak, Jeannie Hoffman-Censits, Yujia Wen, Olwen Hahn, Cecilia Mitchell, Alan Tan, Howard Streicher, Elad Sharon, Helen Moon, Michael Woods, Susan Halabi, Gabriela Perez Burbano, Michael J. Morris, Jonathan E. Rosenberg.

”Honored to coauthor a likely practice changing Phase III clinical trial (Ambassador) from AdventHealth Central Florida Cancer Institute in the New England Journal of Medicine – along with Andrea Apolo from National Cancer Institute (NCI) and colleagues – adjuvant pembrolizumab improved outcomes in muscle invasive urothelial cancer, bladder cancer – disease-free survival was significantly longer with adjuvant pembrolizumab than with observation- median 29.6 vs 14.2 months (HR 0.73; P=0.003) – trial updated at ESMO24 too.”

Source: Guru Sonpavde/LinkedIn